Navigation Links
AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
Date:9/22/2010

ROCHESTER, N.Y., Sept. 22 /PRNewswire-USNewswire/ -- AstraZeneca purchased a one-year membership to gain access to an international repository of data designed to aid industry and academic researchers developing new technologies to improve cardiac safety. The database, called the Telemetric and Holter ECG Warehouse (THEW), helps researchers better evaluate how drugs affect the heart. Cardiac toxicity is one of the leading causes of removal of drugs from the market today, which is why ongoing research in this area is needed.  

THEW is the result of a partnership between the University of Rochester Medical Center, the U.S. Food and Drug Administration (FDA) and the National Heart, Lung and Blood Institute of the National Institutes of Health. THEW consists of a digital catalogue of continuous electrocardiographic recordings from cardiac patients and healthy individuals, as well as electrocardiograms from safety studies implemented by major pharmaceutical companies.  

In addition to helping industry and academic researchers better understand the electrical activity of the heart and how individual drugs may influence this activity, the data may aid the development of new tools to more easily detect drugs that can have dangerous effects on the heart. With the THEW partnership, AstraZeneca will gain full access to a wide range of electrocardiographic recordings and the associated clinical information that can be used to develop, implement and validate electrocardiographic markers of drug cardiotoxicity.

"We believe AstraZeneca's interest and involvement in our initiative is an important milestone. The support we have received from major pharmaceutical companies has grown over time and further validates our decision to develop a repository for scientific data for the development of novel technologies related to cardiac safety," said Jean-Philippe Couderc, Ph.D., M.B.A., associate professor in the Division of Cardiology at the University of Rochester Medical Center and director of the THEW project.

Companies may purchase a year-long, full-access membership, or they may purchase access to individual databases within THEW. Membership information can be found on the THEW website at www.thew-project.org.

"We are glad to generate opportunities for pharmaceutical companies to evaluate their cardiac safety technologies using the data from our repository. Over the past two years, we have helped companies improve their ECG tools and several of these tools have had a profound impact on the way companies assess cardiac safety," said Couderc.

The THEW database is part of the Center for Quantitative Electrocardiography and Cardiac Safety, which is a component of URMC's Heart Research Follow-up Program. The Program is an international leader in the science of heart arrhythmias and a rare genetic condition associated with an abnormal QT interval, called the congenital Long QT Syndrome (LQTS). URMC keeps an International Registry for LQTS, and follows thousands of families who have this inherited condition. One of the genetic forms of the QT prolongation syndrome is similar to the drug-induced syndrome, and the university's work focuses on developing the tools to identify individuals with either condition.

One of the nation's top academic medical centers, the University of Rochester Medical Center (http://www.urmc.rochester.edu) forms the centerpiece of the University's health research, teaching, patient care, and community outreach missions. The Medical Center receives more than $240 million in external research funding per year and the University of Rochester School of Medicine and Dentistry ranks in the top one-quarter of U.S. medical centers in federal research funding. The University's health care delivery network is anchored by Strong Memorial Hospital – a 754-bed, University-owned teaching hospital.  As upstate New York's premier health care delivery network, patients benefit from the Medical Center's robust teaching and biomedical research programs.


'/>"/>
SOURCE University of Rochester Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca and Grace Hill Neighborhood Health Centers, Inc. Provide Medicines to Missouris Uninsured
2. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
3. FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZenecas SYMBICORT
4. AstraZeneca to Support Drug-Induced Liver Injury Network at the National Institutes of Health
5. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
6. Remarks as Prepared for Delivery By Attorney General Eric Holder at the AstraZeneca Settlement Announcement
7. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
8. Palatin Technologies, Inc. Receives $2.5 Million from AstraZeneca
9. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
10. AstraZeneca and Dako Sign Agreement to Develop Companion Diagnostics for Cancer Treatments
11. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... The American Pharmacists Association (APhA) is excited ... Medically Underserved Areas Enhancement Act (H.R. 592) ... was previously introduced in the 114 th session ... through pharmacists and their patient care services. ... (R-KY), G.K. Butterfield (D-NC), Tom ...
(Date:1/23/2017)... ALBANY, New York , January 23, 2017 ... Non-Invasive Prenatal Testing Market was valued at US$0.53 bn ... by expanding at a strong 17.50% CAGR between 2014 and 2022. ... - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ... ...
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... , ... "Photo Cloud allows FCPX users to add favorited photos to any ... said Christina Austin - CEO of Pixel Film Studios. , To begin, select ... Presets include scenes with one, three, four or five focus points. There are five ...
(Date:1/21/2017)... ... ... Caronlab Australia, an Australian company known for health and beauty products such ... where it benefited from outstanding meetings with major retail buyers. , Caron Labs has ... this trade show, the company had the chance to demonstrate its products and provide ...
(Date:1/21/2017)... ... ... perfect set of tools for video editors that want to create the illusion of rack ... of Pixel Film Studios. , Video editors using ProDOF can add realistic depth of ... from one area into the next. ProDOF comes with 0.5 second, 1.0 second, 1.5 ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to ... the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of ... Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... announce that Redwood Family Dermatology has recently joined their multi-specialty medical ... a full range of cosmetic services. , “We’re excited to add this excellent ...
Breaking Medicine News(10 mins):